ANI Pharmaceuticals Inc (ANIP) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ANI Pharmaceuticals Inc stock $141, price $67.41, upside +109.1%, quality 57 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $23.09 – $98.81 · fair‑value band $72.62 – $206.08 · the $67.41 price screens below the $140.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow ANI Pharmaceuticals in your weekly email
Every Wednesday you see whether ANI Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Show moreShow less
It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers.
ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Stock analysis
ANI Pharmaceuticals Inc (ANIP) currently trades at $67.41, while our model-based Fair Value estimate is $140.94, implying the stock looks roughly 52% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $158.52 per share, and 16 of the 22 models we run sit above the $67.41 price.
Bear case: the Economic Profit group reads lowest at $21.59, and 6 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $72.62 (bear) to $206.08 (bull), the price of $67.41 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ANI Pharmaceuticals Inc reported revenue of $883M in FY2025 versus $216M in FY2021, a compound +42.2%/yr. Reported net income was $78.3M in FY2025.
Key figures
Market cap $1.6B Small · P/E ratio 14.6 · P/S ratio 1.64 · EPS (TTM) $4.62 · Net margin 11.1% · Return on equity 20.5% · Return on assets (EBIT) 0.2% (5-year average) · Operating margin 15.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 25% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 109%, ANIP screens cheaper than that median.
Fair Value models
Bear$72.62Fair Value $140.94Bull$206.08
Price $67.41 · Upside +109.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.95 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 8 officers or directors sold shares worth $9.2M and none bought.
SaleStephen P. CareySVP & CFO8× since Mar 5, 2026: 28,187 shares, avg. $77.93$2.2MOct 29, 2026
SaleNikhil LalwaniPRESIDENT & CEO, Director4× since May 11, 2026: 71,200 shares, avg. $76.39$5.4MOct 15, 2026
SaleMeredith CookSR. VP, GENERAL COUNSEL & SEC.12× since Nov 13, 2025: 5,800 shares, avg. $78.38$454,631Oct 13, 202610b5-1 plan
SaleJeanne ThomaDirector1,000 shares at $71.53$71,530Sep 11, 202610b5-1 plan
SaleOri GutwergSVP, GENERICS3× since Mar 3, 2026: 7,994 shares, avg. $77.74$621,438Aug 10, 2026
SaleThomas HaugheyDirector2,000 shares at $80.88$161,760Jun 8, 202610b5-1 plan
SalePatrick D WalshDirector3× since Nov 13, 2025: 28,616 shares, avg. $81.19$2.3MMay 13, 2026
SaleThomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS2× since Mar 11, 2026: 5,231 shares, avg. $75.29$393,828May 12, 2026
SaleChristopher MutzHEAD OF RARE DISEASE5× since Feb 12, 2026: 21,657 shares, avg. $75.52$1.6MMar 13, 202610b5-1 plan
SaleKrista DavisSVP, CHIEF HR OFFICER3× since Dec 18, 2025: 12,008 shares, avg. $76.50$918,622Mar 9, 202610b5-1 plan
Plus 2 more entries from the last 12 months.
Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+43.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
Start year 2020 (pandemic). Over 10 years: +27.7% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
≈ +78.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +78.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.48.8% vs 10.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8% → 9%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.20 per share, median 1.27 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −1.9% a year for the price and +9.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare ANI Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+109.1% · Top 25%
Profitability
Return on equity (12 months)20.5% · Top 25%
Return on assets5.4% · Above median
Net margin (12 months)11.1% · Above median
Operating margin (12 months)15.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)25.9% · Top 25%
Balance sheet
Debt / equity1.11× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)14.6× · Cheaper than median
P/B2.96× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ANI Pharmaceuticals Inc (ANIP) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $140.94 versus a price of $67.41, about +109% upside (undervalued).
What is the fair value of ANIP?
Our model-based fair value for ANI Pharmaceuticals Inc is $140.94 (as of Nov 6, 2026), built from audited fundamentals. The current price: $67.41.
What is the quality score of ANIP?
ANI Pharmaceuticals Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ANI Pharmaceuticals Inc (ANIP)?
Our model-based price target is the fair value of $140.94 (as of Nov 6, 2026) from 22 valuation models. Cautious scenario $72.62, optimistic scenario $206.08. It is a calculation from audited fundamentals, not an analyst target.
What is the ANI Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $140.94, about +109% upside versus a price of $67.41 (undervalued). Cautious scenario $72.62, optimistic scenario $206.08. The calculation is refreshed regularly with new filings.
What is the revenue of ANI Pharmaceuticals Inc (ANIP)?
ANI Pharmaceuticals Inc reported trailing-twelve-month revenue of about $978M (latest available figure, as of Nov 6, 2026).
Does ANI Pharmaceuticals Inc pay a dividend?
ANI Pharmaceuticals Inc does not currently pay a dividend.
What growth is priced into ANI Pharmaceuticals Inc (ANIP)?
For today's price to be fair in a discounted-cash-flow model, ANI Pharmaceuticals Inc would have to grow free cash flow by +0.5 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +33.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ANIP use?
Our models discount ANI Pharmaceuticals Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.47, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ANI Pharmaceuticals Inc that is +0.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has ANI Pharmaceuticals Inc (ANIP) delivered so far?
Over the past 5 years revenue at ANI Pharmaceuticals Inc grew +33.5 % a year. The price currently implies free-cash-flow growth of +0.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ANI Pharmaceuticals Inc (ANIP) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into ANI Pharmaceuticals Inc (+0.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ANI Pharmaceuticals Inc (ANIP)?
The free-cash-flow yield on the price is 10.21 %: that much free cash flow ANI Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ANI Pharmaceuticals Inc (ANIP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ANI Pharmaceuticals Inc it is $140.94 per share (as of Nov 6, 2026), against a price of $67.41. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is ANI Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ANIP trades below its calculated fair value: price $67.41, fair value $140.94, a gap of about +109% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANIP?
No. The price is what the market pays today ($67.41); the fair value is what the company's own numbers justify ($140.94). For ANI Pharmaceuticals Inc the two are $73.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is ANI Pharmaceuticals Inc worth?
The market values ANI Pharmaceuticals Inc at about $1.6B (market capitalisation, as of Nov 6, 2026). Per share that is $67.41; our models calculate a fair value of $140.94 per share.
What do the bullish and bearish scenarios say about ANIP?
Our models span a range for ANI Pharmaceuticals Inc: cautious scenario $72.62, base $140.94, optimistic $206.08 per share (as of Nov 6, 2026, price $67.41). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ANIP?
ANI Pharmaceuticals Inc trades at a price-to-earnings ratio of 14.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $140.94 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2016 to 2025), reported earnings, FY2016, FY2023 ex one-offs: 75.0. Other multiples: PEG 1.8, P/B 3.0, P/S 1.6, EV/EBITDA 9.1.
What is the PEG ratio of ANIP?
The PEG ratio of ANI Pharmaceuticals Inc is 1.78 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ANI Pharmaceuticals Inc (ANIP)?
Balance-sheet figures for ANI Pharmaceuticals Inc (as of Nov 6, 2026): return on equity 20.5%, debt of 1.11 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is ANIP from its 52-week high?
ANI Pharmaceuticals Inc trades at $67.41, about 25% below its 52-week high of $90.43 and at the low of $67.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $140.94 is for.
Which stocks are comparable to ANI Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ANI Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $67.41, calculated fair value $140.94 (+109%), Quality Score 57/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANIP calculated?
We run ANI Pharmaceuticals Inc through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $140.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. ANI Pharmaceuticals Inc currently trades 52% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ANI Pharmaceuticals Inc (ANIP)?
The closing price on Nov 6, 2026 was $67.41. Our model-based fair value is $140.94, about +109% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ANI Pharmaceuticals Inc right now?
The price is below even our cautious bear case ($72.62). The market is more pessimistic than our downside scenario. The model range is unusually wide ($72.62 to $206.08). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of ANI Pharmaceuticals Inc (ANIP) come from?
Earnings per share at ANI Pharmaceuticals Inc grew +6.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +18.3 %, EBIT margin −11.4 %, tax rate −1.5 %, residual (interest, one-offs) +3.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ANI Pharmaceuticals Inc
How large is the market capitalisation of ANI Pharmaceuticals Inc (ANIP)?
The market capitalisation of ANI Pharmaceuticals Inc is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ANI Pharmaceuticals Inc (ANIP)?
The price-to-sales ratio of ANI Pharmaceuticals Inc is 1.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ANI Pharmaceuticals Inc (ANIP)?
Earnings per share at ANI Pharmaceuticals Inc are $4.62 (price ÷ EPS = P/E 14.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ANI Pharmaceuticals Inc (ANIP)?
The net margin of ANI Pharmaceuticals Inc is 11.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ANI Pharmaceuticals Inc (ANIP)?
The return on equity (ROE) of ANI Pharmaceuticals Inc is 20.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ANI Pharmaceuticals Inc (ANIP)?
On an EBIT basis the return on assets of ANI Pharmaceuticals Inc is 0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ANI Pharmaceuticals Inc (ANIP)?
The operating margin of ANI Pharmaceuticals Inc is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ANI Pharmaceuticals Inc (ANIP)?
Revenue at ANI Pharmaceuticals Inc is growing +25.9% versus a year earlier (3y avg +40.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ANI Pharmaceuticals Inc (ANIP)?
Earnings per share at ANI Pharmaceuticals Inc are growing +191% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ANI Pharmaceuticals Inc (ANIP) carry?
The net debt of ANI Pharmaceuticals Inc is $39.6M (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ANI Pharmaceuticals Inc in the live analysis
One click puts ANI Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026